Can the RAS-MAPK Pathway be Targeted Therapeutically?
Yes, the RAS-MAPK pathway is a significant target for therapeutic intervention. Several inhibitors have been developed to target various components of the pathway, such as MEK inhibitors and RAF inhibitors. These therapies are used to treat cancers with specific mutations in the pathway, offering a more tailored approach to treatment.
